nCode Bio is a generative “Sequence-as-a-Service” (SQAAS) platform that leverages advanced AI and deep-learning to generate optimized therapeutic RNA sequences—enhancing cell-type selectivity, optimizing expression, and forecasting immunogenicity. ncodebio.ai+2ncodebio.ai+2
Need:
Traditional discovery of RNA sequences often takes many months, involves trial-and-error, and may yield off-target effects or high immunogenicity.
‍
Solution:
nCode’s AI “Synapse” engine rapidly generates and refines therapeutic sequences, integrating multi-omic data and predictive modeling to reduce time-to preclinical and improve safety/efficacy.
Need:
‍Many therapies fail to achieve desired cell-type specificity, increasing side-effects and reducing efficacy.
Solution:
nCode applies deep-learning and massive parallel micro-experiments (e.g., 10^6 experiments per run) to optimize sequences for precise cell-type targeting and minimal off-target activity.
Need:
Wet-lab validation and iteration of RNA therapies are costly and time-consuming, slowing innovation.
Solution:
nCode integrates high-throughput robotic experimentation, predictive immunogenicity modeling and continuous learning to streamline validation cycles and accelerate sequence optimization.
‍
1.Modular approach for customizable, cohesive solutions
2.Automated workflows and claims processing
3.Reduced administrative complexity
4.Unified care delivery across systems
5.High security and compliance standards
6.Supports healthcare providers in optimizing care delivery and patient outcomes
‍
.png)